Home Ľ NH Angle

October 03. 2013 12:53PM

Manch-based Boston Therapeutics closes $5.3M placement of common stock, warrants

Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes.

CLICK TO VIEW THE SOURCE MATERIAL

 New Hampshire Events Calendar
  

   Ľ SHARE EVENTS FOR PUBLICATION, IT'S FREE!

Arts and Entertainment
Family, Community and Culture
Outdoors, Sports and Recreation

Most Read

Most Comments

Most Shared

New OT rule in AHL generating buzz

Slam thunk! Sarah Silverman nearly hit by basketball at Knicks game... but luckily John McEnroe is there to shield her

Jon Cassidy: They didnít call it dark money when the other side was burning crosses

Allen B. West: Left-leaning AP says police killings of blacks is yearís top story; I vote for Meriam Ibrahim

Concord Monitor finds big government make every day a little like Christmas

Portsmouth Herald: Expanding shipyard significant on many levels